A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Tofacitinib (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions
- 16 Aug 2022 Status changed from not yet recruiting to recruiting.
- 12 Aug 2022 Planned End Date changed from 31 Jan 2025 to 1 Jan 2027.
- 12 Aug 2022 Planned primary completion date changed from 31 Jan 2025 to 1 Jan 2026.